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Summary
Aim: To assess the risk of bias (RoB) in a subset of randomized controlled trials (RCTs) published 
in orthodontic journals using the Cochrane RoB tool and to identify associations between domain 
RoB assessment and treatment effect estimates.
Materials and methods: Fifty consecutive issues of four major orthodontic journals were 
electronically searched to identify RCTs. The quality of the included studies was assessed using 
the Cochrane RoB tool, which involves seven domains rated as ‘low’, ‘unclear’ or ‘high’: random 
sequence generation, allocation concealment, blinding of participants and personnel, blinding 
of outcome assessment, incomplete outcome data, and selective outcome reporting, and other 
threats to internal validity. Estimates and confidence intervals (CIs) were recorded or calculated 
where possible for binary and continuous outcome measures. Meta-regression models were 
employed to assess the impact of RoB per domain on the magnitude of treatment effect.
Results: One hundred and one eligible studies involving 128 pair-wise comparisons were retrieved. 
Blinding of outcome assessors and incomplete outcome data were frequently judged as ‘high’ for 
RoB both for studies with binary and continuous outcome (42.9 and 48.8 per cent, respectively). 
For binary outcomes, high RoB regarding random sequence generation [odds ratio (OR): 5.97, 95% 
CI: 2.03, 17.63, P-value: 0.002] and incomplete outcome data (OR: 4.07, 95% CI: 1.03, 16.15, P-value: 
0.05) were more likely to provide exaggerated effect estimates.
Conclusions: There is a need for improved clinical trial methodology and reporting, in order to 
avoid inflated associations and erroneous conclusions.
Introduction
The importance of randomized controlled trials (RCTs) in informing 
clinical practice and formulating clinical decision-making is widely 
recognized. The value of a clinical trial in guiding clinical decisions is 
dependent on a series of reporting characteristics, providing insight to 
the methodology and any potential risk of bias (RoB) (1). However, 
methodological and reporting deficiencies have been repeatedly 
exposed in RCTs within medicine, dentistry, and orthodontics (2–6).
Systematic reviews (SRs) and meta-analyses concerning the effec-
tiveness of interventions combine the results from RCTs leading to 
a more precise summary estimate and ultimately a recommendation 
for practice. Consequently, RoB inherent in RCTs is likely to influ-
ence the quality of the evidence derived from SRs (7–9). A variety of 
tools have been used to assess the reporting/methodological quality 
or RoB within RCTs (10, 11). The Cochrane Collaboration’s RoB 
tool includes assessment for six types of bias: selection bias, perfor-
mance bias, detection bias, attrition bias, reporting bias, and other 
European Journal of Orthodontics, 2016, 308–312
doi:10.1093/ejo/cjv049
Advance Access publication 14 July 2015
by guest on Decem
ber 7, 2016
D
ow
nloaded from
 
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
94
46
8 
| 
do
wn
lo
ad
ed
: 
6.
1.
20
20
bias within seven domains (11). Each type of bias may arise at dif-
ferent stages of the trial and corresponds to different domains. For 
example, in respect of selection bias the relevant domains are ran-
dom number generation and allocation concealment.
Bias identified in RCTs stems from threats to the internal valid-
ity of the study which might lead to distorted treatment effects and 
may ultimately impact on treatment choices. The magnitude of the 
effect size and its precision is an important parameter, therefore, in 
treatment choices. Previous biomedical literature has exposed asso-
ciations between study internal validity and effect sizes; however, the 
findings were not always consistent (12–14). A recent SR concluded 
that effect sizes are exaggerated by 11–13 per cent for inappropriate 
random number generation or allocation concealment and lack of 
blinding especially if outcomes were subjective (15). There is cur-
rently only one assessment of this possible association within oral 
health literature, whereby in periodontology research no association 
between allocation concealment or blinding of assessors and cor-
responding effect sizes was noted (16). Thus, the aim of the present 
cross-sectional survey was to assess the RoB of RCTs published in 
orthodontic literature using the Cochrane RoB tool and to assess 
potential associations between RoB domains and observed treat-
ment effect estimates.
Materials and methods
RCTs published in major orthodontic journals were included in 
the present study. The contents of the most recent 50 issues of the 
American Journal of Orthodontics and Dentofacial Orthopedics 
(AJODO), the Angle Orthodontist (Angle), the European Journal 
of Orthodontics (EJO), and the Journal of Orthodontics (JO) were 
electronically searched up to November 2013 by two authors (DK 
and EL). Only RCTs were eligible for inclusion. Initially the title and 
abstract were screened; if randomization was apparent or the pro-
spective nature of the study was verified, the full text was accessed 
to clarify trial design. Terminology such as ‘random allocation’, ‘ran-
dom assignment’, ‘randomly divided’ or similar were chosen as indi-
cators of a randomized design.
The quality of the RCTs included was assessed according to the 
Cochrane RoB tool, incorporating the following domains: random 
sequence generation, allocation concealment, blinding of partici-
pants and personnel, blinding of outcome assessment, incomplete 
outcome data, and selective outcome reporting and other potential 
threats to validity. RoB assessment may result in ‘low’, ‘unclear’ or 
‘high’ RoB. Details concerning population characteristics (mean and 
standard deviation or number of events) and sample size per group 
were recorded. Estimates and confidence intervals (CIs) for continu-
ous or dichotomous/time-to-event outcomes were recorded or calcu-
lated where possible.
Fifty percent of the papers were scored independently by two 
authors (DK and EL) to arrive to a consensus assessment, as part of 
a calibration procedure. The rest of the papers were divided between 
the investigators and scored independently. Discrepancies were 
resolved through consultation with a third author (NP).
To assess the impact of RoB on the estimates, a series of simple 
meta-regression models were undertaken for each domain: random 
sequence generation, allocation concealment, blinding of participants 
and personnel, blinding of outcome assessment, incomplete outcome 
data, selective outcome reporting, and other potential threats to 
validity. Continuous and binary data were analysed separately. For 
the analysis, only ‘high’ and ‘unclear’ RoB levels were combined con-
verting each domain into a binary variable, as recommended also in 
the Cochrane Handbook (17). The dependent variable was the trial 
results presented on an odds ratio (OR) scale for binary outcomes 
or as standardized mean difference for continuous outcomes. The 
independent variable was the dichotomized bias score: low RoB and 
unclear/high RoB. Low RoB was used as the reference level.
Among the included studies, some multi-arm studies were iden-
tified; incorporation of multi-arm studies in a joint model was 
attempted but the results were imprecise. Consequently, we decided 
to ‘split’ the control group into two (for the 3-arm studies) or more 
groups with smaller sample size in order to include each pair-wise 
comparison separately without inappropriately inflating sample size. 
Particularly, in the binary dataset both the number of events and the 
total number of patients were separated, whereas in the continuous 
dataset only the total number of participants was split up keeping 
the means and standard deviations as reported (17).
The following confounding parameters were planned for inclusion 
in the meta-regression models: year of publication, recruitment coun-
try, availability of informed consent documentation, number of authors 
involved in the publication, the number of recruiting centres, the study 
design and whether a methodologist was involved in the analysis. The 
involvement of a methodologist was assessed either from reported affil-
iations and/or acknowledgements in the manuscripts. To prevent the 
risk of false positive conclusions due to the presence of many covari-
ates, a Monte Carlo permutation test using 10 000 permutations was 
applied, in order to select the statistically significant covariates (18). 
In the aforementioned meta-regression models, statistical significance 
was inferred at a significance level of 5 per cent. All analyses were per-
formed in Stata 13.0 (Stata Corp, College Station, Texas, USA).
Results
A total of 128 studies were identified. Of these, 24 (18.8 per cent) 
studied a binary outcome (i.e. event or non-event) and the remain-
ing 104 involved a continuous outcome. Among the 24 studies with 
binary outcome, 3 (12.5 per cent) did not provide any outcome data. 
Similarly, among the 104 studies with continuous outcomes, 24 (23.1 
per cent) did not provide any outcome data. Two trials with binary 
outcome studies evaluated three treatments, whereas 17 trials with 
continuous outcome studied three treatments and 1 trial studied five 
treatments. Overall, 101 RCTs were eligible for inclusion, with 119 
comparisons (Supplementary Material online). The majority of stud-
ies were published after 2007 (77/101; 76.2 per cent), were single-
centred (69/101; 68.3 per cent), and were of European authorship 
(62/101; 61.4 per cent). Informed consent was documented in 80 
studies (79.2 per cent). A  considerable amount of studies involved 
less than four authors (38/101; 37.6 per cent), whereas only in one 
in five studies a statistician for the statistical analysis was involved 
(21/101; 20.8 per cent). A breakdown to years of the included issues 
per journal revealed studies published in the AJODO within the years 
2009–13, in the Angle and the EJO between 2006 and 2012 and in 
the JO from 2001 to 2013.
Binary outcome studies
As shown in Table 1, most of the studies with binary outcome were 
parallel-group (66.7 per cent), with the most frequently studied 
effect measure being the hazard ratio followed by the risk difference 
(38.1 and 28.6 per cent, respectively).
The distribution of the RoB in the individual domains assessed 
with the Cochrane Collaboration’s ‘RoB’ tool is illustrated in 
Table 2. More than half trials presenting binary outcomes reported 
insufficient details pertaining to allocation concealment (66.7 per 
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cent), blinding of participants and personnel (85.7 per cent), incom-
plete outcome data (57.1 per cent), and selective outcome reporting 
(90.5 per cent), and as a result, the judgments on the degree of bias 
were unclear. Only detection bias and other sources of bias were 
judged to be high risk (42.9 and 57.1 per cent, respectively). Finally, 
according to the reports random sequence generation was judged as 
appropriate in the majority of these trials (66.7 per cent).
A Monte Carlo permutation test was employed to adjust the type 
I error due to employing a series of single covariate meta-regression 
models. Table 3 provides the P-value results for each single covari-
ate meta-regression model after 10 000 permutations. Without type 
I error adjustment, there is no evidence of association for any covari-
ate (minimum unadjusted P-value = 0.292). After accounting for 
multiplicity, all P-values increased considerably. The standard error 
of the calculated P-values was estimated at 0.005 indicating that 10 
000 random permutations were enough to provide precise results.
Results from a series of single covariate meta-regression models 
are given in Table 4; each covariate reflects a specific domain of the 
RoB tool. A study is more likely to provide larger treatment effect 
when there is unclear or high RoB regarding random sequence gen-
eration (OR: 5.97, 95% CI: 2.03, 17.63, P-value: 0.002) and incom-
plete outcome data (OR: 4.07, 95% CI: 1.03, 16.15, P-value: 0.05) 
and the findings are statistically significant. However, the results 
are based only on a set of 23 comparisons which may explain the 
wide CIs.
Continuous outcome studies
Similar to the studies with binary outcomes, the majority of stud-
ies with continuous outcome were parallel-group (83.8 per cent), 
(Table 1).
More than 70 per cent of the trials reported insufficient details 
pertaining to allocation concealment (72.5 per cent, Table 2), blind-
ing of participants and personnel (82.5 per cent) and selective out-
come reporting (92.5 per cent), whereas only blinding of outcome 
assessment and other sources of bias were judged to be at high RoB 
in a considerable number of the studies (48.8 and 41.3 per cent, 
respectively). For almost half of the studies attrition bias and other 
sources of bias were judged to be unclear. Only random sequence 
generation was judged to be of low RoB in the majority of these 
trials (57.5 per cent).
The Monte Carlo permutation results on P-value for each single 
covariate meta-regression model are outlined in Table  3. Without 
type I error adjustment, there is weak evidence that informed consent 
may have an impact on the study results (smaller P-value = 0.056). 
After accounting for multiplicity, all P-values increase considerably 
(smaller P-value = 0.338). Similar to studies with binary outcome, 
the standard error of the calculated P-values was estimated at 0.005 
indicating that 10 000 random permutations were enough to pro-
vide precise results.
The results from a series of single covariate meta-regression 
models on the standardized mean difference scale are presented in 
Table 4. The first arm (active intervention/new intervention) is more 
likely to provide smaller treatment effect than the comparator (con-
trol/standard intervention) when there is high/unclear RoB regarding 
random sequence generation, blinding of participants and person-
nel, blinding of outcome assessment, selective outcome reporting, 
and other potential threats to study validity (SMD: −0.26, −0.005, 
−0.002, −0.27, and −0.31, respectively). However, all CIs include the 
zero value reflecting no difference between the arms for high/unclear 
and low RoB. In addition, the impact of blinding of personnel and 
blinding of outcome assessment on the treatment effects was almost 
negligible (−0.005 and −0.002, respectively).
Discussion
RoB assessment in a representative subset of RCTs published in major 
orthodontic journals resulted in judgment as ‘unclear’ for more than 
half of the studies in at least four of the RoB domains including alloca-
tion concealment, blinding of participants and personnel, incomplete 
outcome data, and selective outcome reporting. RoB was judged as 
‘unclear’ when there was insufficient information available to permit 
judgment of ‘high’ or ‘low’ RoB. Blinding of participants or personnel 
Table 1. Distribution of several study characteristics, by outcome 
type (n = 101 studies).
Characteristic
Frequency (%)*
Binary Continuous
Study type
Parallel 14 (66.67) 67 (83.75)
Split mouth 7 (33.33) 8 (10.00)
Crossover 0 5 (6.25)
Effect estimate
Mean/median diff NA 80 (100.00)
Risk ratio 4 (19.05) NA
Odds ratio 3 (14.29) NA
Hazard ratio 8 (38.10) NA
Risk difference 6 (28.57) NA
Total 21 (100) 80 (100)
Mean/median diff: mean or median difference; NA: not applicable.
*The results are presented as counts and row percentage in the parenthe-
ses by type of outcome.
Table 2. Distribution of the risk of bias across type of outcome (n = 101 studies).
Source of bias
Binary* Continuous*
Low Unclear High Low Unclear High
Random sequence generation 14 (66.67%) 5 (23.81%) 2 (9.52%) 46 (57.50%) 32 (40.00%) 2 (2.50%)
Allocation concealment 7 (33.33%) 14 (66.67%) 0 (0.0%) 20 (25.00%) 58 (72.50%) 2 (2.50%)
Blinding of participants and personnel 3 (14.29%) 18 (85.71%) 0 (0.0%) 10 (12.50%) 66 (82.50%) 4 (5.00%)
Blinding of outcome assessment 5 (23.81%) 7 (33.33%) 9 (42.86%) 34 (42.50%) 7 (8.75%) 39 (48.75%)
Incomplete outcome data 5 (23.81%) 12 (57.14%) 4 (19.05%) 22 (27.50%) 36 (45.00%) 22 (27.50%)
Selective outcome reporting 0 (0.0%) 19 (90.48%) 2 (9.52%) 5 (6.25%) 74 (92.50%) 1 (1.25%)
Other sources of bias 3 (14.29%) 6 (28.57%) 12 (57.14%) 11 (13.75%) 36 (45.00%) 33 (41.25%)
*The results are presented as counts and row percentage in the parentheses by type of outcome.
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involved in an orthodontic trial may be inapplicable due to the nature 
of the interventions provided. Inapplicability of blinding does not nec-
essarily indicate low methodological quality; however, the potential 
RoB due to lack of blinding cannot be ignored. Moreover, blinding of 
outcome assessors was frequently judged to be of high RoB whereas 
random sequence generation was frequently judged to be of low RoB. 
These findings underscore not only the compromised internal validity 
of RCTs in orthodontic research, but also the apparent weaknesses in 
trial reporting which is not new to biomedical literature (5, 19–23). 
Suboptimal reporting and deficient adherence to reporting guidelines 
of medical and dental RCTs remains a problem, despite the wide-
spread adoption of the Consolidated Standards for Reporting of Trials 
statement by journals and editorial policies (3, 5, 24).
Significant associations between treatment effects and RoB 
domains were identified solely in studies assessing binary outcomes 
in the present cross-section of RCTs. Reports with high/unclear RoB 
in random sequence generation and incomplete outcome data were 
more likely to provide an exaggerated treatment effect compared 
to those with low RoB scores. However, RCTs bearing results for 
continuous outcomes did not reveal any evidence between RoB and 
treatment effects. In a similar study undertaken in periodontology, 
trials from five Cochrane SRs were explored in terms of two domains 
from the Cochrane RoB tool, and neither allocation concealment 
nor examiner blinding could be associated with the magnitude of 
treatment outcomes (16). Conversely, evidence from biomedical lit-
erature in a breadth of clinical trials contributing to meta-analyses 
has raised awareness with regard to the influence of reported study 
design characteristics on the intervention effect estimates from RCTs 
(15). Among others, treatment effects of trials with inadequate or 
unclear random sequence generation, allocation concealment and 
‘double blinding’ have appeared exaggerated by a factor of 7 to 13 
per cent, and have been exposed as inflated by up to 15–17 per cent 
in a subgroup of studies addressing subjective outcomes. Evidence 
from pregnancy and childbirth research has revealed exaggerated 
ORs by as much as 41 per cent, when concealment of allocation was 
inadequate (13).
The effects of other sources of bias such as attrition bias or 
reporting bias in the results from clinical trials have not been pre-
viously assessed. An association of attrition bias and exaggerated 
treatment effects was recorded in the present study. Losses to follow 
up or incomplete accounting for dropouts may risk inflated effect 
sizes to either direction and erroneous study conclusions due to 
between-group discrepancies (25). This is of particular importance 
in the clinical context of orthodontics or other medical fields where 
treatment effectiveness is largely dependent on the cooperation/com-
pliance of trial participants to the allocated intervention (19).
A subset of orthodontic journals was searched to provide a rep-
resentative cross-section of orthodontic RCTs in the present study; 
these represent the major journals within the clinical field of ortho-
dontics. While it is likely that some RCTs over the study period have 
not been identified, these journals are known to publish the high-
est frequency of RCTs (20) with adequate reporting profiles (4). No 
attempt was made to contact authors of included studies for further 
clarification with regard to study design and conduct which may 
have had an effect on our judgment on internal validity of the pri-
mary study. However, contact with authors is notorious for lead-
ing to post hoc conclusions that lack credibility (26). Moreover, in 
the analysis a decision was made to combine ‘high’ and ‘unclear’ 
RoB levels allowing each domain to be converted into a binary 
variable. While this approach may have resulted in loss of data, it 
has been recommended (17) with the majority of empirical studies 
Table 4. Single covariate meta-regression results (n = 119 comparisons). OR, odds ratio; CI, confidence interval; SMD, standardized mean 
difference; Ref, reference.
Covariate Risk of bias
Binary Continuous
OR 95% CI P-value SMD 95% CI P-value
Random sequence generation Low Ref Ref
Unclear/high 5.97 2.03 to 17.63 0.002 −0.26 −0.81 to 0.29 0.35
Allocation concealment Low Ref Ref
Unclear/high 2.54 0.68 to 9.44 0.17 0.04 −0.58 to 0.67 0.89
Blinding participants and personnel Low Ref Ref
Unclear/high 0.57 0.08 to 3.88 0.55 −0.005 −0.77 to 0.76 0.99
Blinding outcome assessment Low Ref Ref
Unclear/high 0.63 0.13 to 3.08 0.55 −0.002 −0.55 to 0.54 0.99
Incomplete outcome data Low Ref Ref
Unclear/high 4.07 1.03 to 16.15 0.05 0.05 −0.58 to 0.67 0.89
Selective outcome reporting* Low Ref Ref
Unclear/high NA NA NA −0.27 −1.25 to 0.70 0.58
Other sources of bias Low Ref Ref
Unclear/high 1.92 0.31 to 12.13 0.47 −0.31 −1.07 to 0.45 0.42
Statistically significant results are highlighted in bold and italic. NA, not applicable.
*Selective outcome reporting for binary outcomes was dropped by the model because of collinearity (all comparisons were rated as unclear/high risk of bias).
Table 3. Monte Carlo permutation results on P-value.
Model
Binary* Continuous**
Unadjusted Adjusted Unadjusted Adjusted
Publication year 0.292 0.903 0.743 1.000
Country 0.313 0.922 0.114 0.562
Informed consent 0.807 1.000 0.056 0.338
Number of authors 0.843 1.000 0.483 0.993
Statistician 0.602 0.999 0.766 1.000
Number of centres 0.513 0.993 0.692 1.000
Type of study 0.178 0.747 0.695 1.000
*Largest Monte Carlo standard error of P-value equal to 0.005 for binary 
outcome.
**Largest Monte Carlo standard error of P-value equal to 0.005 for 
continuous outcome.
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undertaking this to facilitate comparison with studies having low 
RoB. In addition, we decided to convert multi-arm studies into two-
arm studies by ‘splitting’ the control group into two or more groups 
with smaller. We recognize that employing such an approach may 
also result in some loss of data.
Conclusions
The RoB in a large subset of orthodontic clinical trials was often 
adjudged to be either high or unclear with particular shortcomings 
including blinding of outcome assessors. High RoB RCTs regard-
ing random sequence generation and incomplete outcome data were 
liable to provide exaggerated treatment effects. Improved clinical 
trial methodology and greater clarity of research reporting within 
dental trials are required to allow quality assessment and better use 
of research findings. Active adoption of reporting guidelines by clini-
cal trial methodologists and researchers, as well as greater editorial 
awareness and contribution to identify malpractices, will guarantee 
improved conduct and reporting of clinical trials and facilitate evi-
dence-based decision-making.
Supplementary material
Supplementary material is available at European Journal of 
Orthodontics online.
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